If retatrutide reduces major cardiovascular events (like semaglutide did in SELECT), the heart rate increase will be viewed as a pharmacologically interesting but clinically irrelevant side effect
Semaglutide acts systemically by reducing caloric load through pronounced weight loss and glycemic control, producing the highest rates of histologic MASH resolution reported to date, albeit with less direct antifibrotic efficacy and characteristic gastrointestinal tolerability issues
Inactive constituents: Sodium chloride, disodium phosphate dihydrate, and water
Since February 2026, BPC-157 is back on the Category 1 list, meaning any licensed pharmacy can compound it
2 and 3 (download XLS Source data ( n , LSM, s.e., P values) included in the submission
If you are not sure which formulation works for your condition, you should consult your doctor first